PTAB Scraps 2 Teva Copaxone Drug Patents After Review
The Patent Trial and Appeal Board has invalidated two patents licensed to Teva Pharmaceuticals USA Inc. for its multiple sclerosis drug Copaxone following an inter partes review proceeding initiated by Mylan...To view the full article, register now.
Already a subscriber? Click here to view full article